TABLE 1.
Regulation of p53 in ferroptosis network.
| Downstream regulation of p53 | Ferroptosis network alternations | Cancer type | Stress condition | Ways of regulation | References |
|---|---|---|---|---|---|
| SLC7A11 | Regulate cystine metabolism | Human osteosarcoma U2OS cells | Nutlin-3 treatment; DNA damage | Positive regulation | Jiang et al. (2015) |
| Saint-Germain et al. (2017) | |||||
| Yuan et al. (2022) | |||||
| SAT1 | Oxidize polyunsaturated fatty acids; increase lipid peroxidation | Melanoma cell line, A375 | Nutlin and ROS treatment | Positive regulation | Ou et al. (2016) |
| Saint-Germain et al. (2017) | |||||
| GLS2 | Reduce GSH; increase ROS | Human glioblastoma; HCC | Doxycycline existence; unstressed condition | Positive regulation | Hu et al. (2010) |
| Wang et al. (2016) | |||||
| Jennis et al. (2016) | |||||
| PTGS2 | Regulate crucial membrane phospholipid; affect polyunsaturated fatty acids abundance and distribution | P533KR/3KR Mdm2−/−embryos | Not mentioned | Positive regulation | Jiang et al. (2015) |
| ALOX12 | Activate lipoxygenase; induce ferroptosis | Human osteosarcoma cell | ROS stress | Positive regulation | Chu et al. (2019) |
| TIGAR | Maintain reduced state of GSH | Lung cancer cell | Adriamycin treatment | Positive regulation | Bensaad et al. (2006) |
| Wang et al. (2016) | |||||
| FDXR | Promote p53 expression; interact with p53; regulate iron metabolisms | Human colon cancer cells | Not mentioned | Positive regulation | Zhang et al. (2017) |
| PARK2 | Eliminate damaged mitochondria; enhance GSH; reduce ROS | Lung cancer cells | Infrared radiation | Negative regulation | Zhang et al. (2011) |
| CDKN1A/p21 | Consume intracellular GSH; reduce ROS level | Fibrosarcoma cells | Cystine deprivation; GPX4 inhibition | Negative regulation | Tarangelo et al. (2018) |
| iPLA2β | Downregulation of peroxidized membrane lipids | Melanoma cells | Nutlin; doxorubicin | Negative regulation | Chen et al. (2021) |
| DPP4 | Diminish lipid peroxidation | Colorectal cancer | DPP4 inhibitor vildagliptin | Negative regulation | Xie et al. (2017) |
ALOX12, Arachidonic acid 12 lipoxygenases; ALOX15, Arachidonic acid 15 lipoxygenases; CDKN1A/p21, Cyclin-dependent kinase inhibitor; DPP4, Dipeptidyl peptidase-4; FDXR, ferredoxin reductase; GLS2, glutaminases; PARK2, Parkinson disease 2; PTGS2, Prostaglandin-endoperoxide synthase 2; SAT1, Spermidine/spermine N1-acetyltransferase; TIGAR, TP53-induced glycolysis and apoptosis regulator.